Novo Nordisk is hitting the gas on amycretin development. After posting phase 2 data, the company has decided to run pivotal diabetes trials of an asset that it previously saw primarily as an obesity ...

A Novo Nordisk challenge has driven a Pennsylvania-based telehealth company to voluntarily discontinue compounded semaglutide product claims, adding to the Danish drugmaker’s string of wins against ...

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Within the next two weeks ...

Facing increased competition in the weight loss market and intense pressure from President Donald Trump, Novo Nordisk announced Monday that it is lowering prices for its blockbuster obesity and ...

Google is updating the Gemini app today with a better way to use photo-to-video generation by adding visual ingredients. You can now upload up to three reference images to guide Veo in the Gemini app.

Novo Nordisk has reported the mixed midphase results behind its push to enter a heart disease market served by Alnylam Pharmaceuticals, BridgeBio and Pfizer. The phase 2 trial compared two doses of ...

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Pfizer has won the ...

NEW YORK/LONDON, Nov 6 (Reuters) - The Pfizer (PFE.N), opens new tab and Novo Nordisk (NOVOb.CO), opens new tab battle for obesity drug developer Metsera (MTSR.O), opens new tab intensified on ...

Novo Nordisk A/S shares have plunged nearly 70%, yet the company remains a leader in GLP-1 and obesity drugs with strong growth catalysts. Despite fierce competition and a recent reset phase, NVO's Q3 ...

O que acontece no corpo quando paramos de comer açúcar? Câmara dos EUA aprova medida para forçar divulgação dos arquivos de Epstein por 427 votos a 1 Fabricante de automóveis chinesa tenta imitar ...

Pressured by its top shareholder, Novo Nordisk on Tuesday said key board members will be replaced. Pressured by its key shareholder, the Novo Nordisk Foundation, the company said its chairman, Helge ...

The Food and Drug Administration approved Novo Nordisk’s NOVO.B-0.84%decrease; red down pointing triangle oral GLP-1 medication to reduce the risk of major cardiovascular events in high-risk adults ...